News|Articles|May 13, 2026

BIOSECURE and Beyond: What it Really Means for Pharma Supply Chains

Barbara Morgan examines how the BIOSECURE act will affect supply chains.

The US pharmaceutical industry is entering a new phase of supply chain transformation. Regulatory pressure, geopolitical uncertainty, new patient populations, and innovative modalities are forcing companies to rethink not only where medicines are produced, but how they move across an increasingly complex global landscape.

Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.